Selumetinib gets the U.S. Breakthrough Therapy Designation
Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and/or progressive, inoperable neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN)- a rare genetic condition, has been granted the Breakthrough Therapy Designation (BTD) from the U.S. FDA. Selumetinib is a MEK- ½ inhibitor jointly developed by AstraZeneca and Merck has shown promising improvements and proven to be of clinical significance.
FDA approves the first drug for a type of inflammatory arthritis
In the very first, the U.S. FDA has approved Cimzia (certol...
